BioPharmSignal logoBioPharmSignal

Biotech News

Exagen Inc. Reports First Quarter 2026 Results

Exagen (XGN)ExagenEarnings

Delivers record total revenue and AVISE(R) CTD average selling price CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.

Related news

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

HCWBHCW Biologics2026-08-14 19:15 EST

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

LUCDLucid Diagnostics2026-08-13 12:00 EST

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

SERASera Prognostics2026-08-12 20:05 EST

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

MREOMereo BioPharma2026-08-11 12:15 EST

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

STTKShattuck Labs2026-08-11 10:15 EST

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

APGEApogee Therapeutics2026-08-10 11:00 EST

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

View all latest news

Exagen

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

XGNExagen2026-06-01 13:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

Stock data

Close
6.70 USD
Market cap
116.45M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States